Human Papillomavirus (HPV) infection causes cervical cancer, a significant portion of anal,
vulvar, vaginal, and oropharyngeal cancers, genital warts, and recurrent respiratory …

Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are
currently in human clinical trials. The main long-term goal of the vaccine is to reduce the …

Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the
second most common cause of death from cancer among women worldwide. This Review …

HPV-associated diseases, such as cervical and other anogenital cancers, cervical and anal
intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis confer …

Vaccination to prevent human papillomavirus (HPV)-related infection leading to cancer,
particularly cervical cancer, is a major public health breakthrough. There are currently two …

Human papillomavirus (HPV) infection can lead to significant disease in males, including
anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital …

Viruslike particles (VLPs) produced from the L1 protein of several papillomaviruses have
induced protection from infection after live challenge in animal models. In the present study …

In this paper, we review the published evidence about the long-term efficacy of the available
human papillomavirus (HPV) vaccines and their safety profile. Two prophylactic HPV …

Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …

Objective: Administration of a quadrivalent HPV-6/11/16/18 vaccine to 16-to 26-year-old
women was highly effective in preventing HPV-6/11/16/18-related cervical/vulvar/vaginal …